In the midst of economic uncertainties and fluctuating indices, the European market has been navigating challenges such as U.S. trade tariffs and monetary policy shifts, with major stock indexes showing mixed performances. Despite these hurdles, opportunities arise for discerning investors to identify undervalued stocks that may offer potential value in a volatile environment.
Top 10 Undervalued Stocks Based On Cash Flows In Europe
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Telefonaktiebolaget LM Ericsson (OM:ERIC B) | SEK83.36 | SEK164.66 | 49.4% |
| Fondia Oyj (HLSE:FONDIA) | €5.45 | €10.63 | 48.7% |
| JOST Werke (XTRA:JST) | €50.00 | €98.51 | 49.2% |
| Storytel (OM:STORY B) | SEK92.70 | SEK180.62 | 48.7% |
| dormakaba Holding (SWX:DOKA) | CHF680.00 | CHF1358.27 | 49.9% |
| Star7 (BIT:STAR7) | €6.20 | €12.36 | 49.8% |
| Cint Group (OM:CINT) | SEK6.40 | SEK12.79 | 49.9% |
| Neosperience (BIT:NSP) | €0.53 | €1.06 | 49.9% |
| Cavotec (OM:CCC) | SEK17.35 | SEK34.07 | 49.1% |
| Fodelia Oyj (HLSE:FODELIA) | €7.12 | €13.91 | 48.8% |
Let's uncover some gems from our specialized screener.
ASML Holding (ENXTAM:ASML)
Overview: ASML Holding N.V. specializes in providing lithography solutions essential for semiconductor equipment systems, with a market capitalization of approximately €257.88 billion.
Operations: The company's revenue is primarily generated from its Semiconductor Equipment and Services segment, which accounted for €28.26 billion.
Estimated Discount To Fair Value: 15.7%
ASML Holding's recent strategic partnership with imec underscores its commitment to innovation and sustainability in the semiconductor industry. The stock trades at approximately €655.7, below its estimated fair value of €778.05, suggesting potential undervaluation based on cash flows. Despite insider selling, ASML is expected to achieve annual earnings growth of 15.4%, surpassing the Dutch market average, while maintaining a high return on equity forecasted at 45.9% over three years.
- The analysis detailed in our ASML Holding growth report hints at robust future financial performance.
- Click here and access our complete balance sheet health report to understand the dynamics of ASML Holding.
Airbus (ENXTPA:AIR)
Overview: Airbus SE, along with its subsidiaries, is involved in the design, manufacture, and delivery of aeronautics and aerospace products, services, and solutions globally with a market cap of approximately €133.32 billion.
Operations: The company's revenue is primarily generated through its segments: Airbus Helicopters (€7.94 billion), Airbus Defence and Space (€12.08 billion), and Airbus, which includes Holding Function and Bank Activities (€50.65 billion).
Estimated Discount To Fair Value: 47.1%
Airbus is trading at €169.2, significantly below its estimated fair value of €319.77, highlighting potential undervaluation based on cash flows. Earnings have grown 42.2% annually over the past five years and are forecast to grow 17.3% per year, outpacing the French market's average growth rate. Recent regulatory approval in China for value-added telecom services could enhance revenue streams, while ongoing negotiations with Spirit AeroSystems may impact future operations and asset allocations in Belfast.
- According our earnings growth report, there's an indication that Airbus might be ready to expand.
- Click to explore a detailed breakdown of our findings in Airbus' balance sheet health report.
Carl Zeiss Meditec (XTRA:AFX)
Overview: Carl Zeiss Meditec AG is a medical technology company operating in Germany, the rest of Europe, North America, and Asia with a market cap of approximately €5.61 billion.
Operations: The company's revenue is primarily derived from two segments: Ophthalmic Devices, including Surgical Ophthalmology, which contributes approximately €1.61 billion, and Microsurgery, which accounts for about €467.36 million.
Estimated Discount To Fair Value: 30.5%
Carl Zeiss Meditec is trading at €64.1, significantly below its estimated fair value of €92.21, suggesting undervaluation based on cash flows. Despite a decline in net income to €15.7 million from €37.4 million year-over-year, earnings are expected to grow over 20% annually, surpassing the German market's growth rate of 16.5%. Recent FDA approval for the MEL 90 excimer laser could bolster revenue through expanded offerings in U.S. refractive clinics.
- Our comprehensive growth report raises the possibility that Carl Zeiss Meditec is poised for substantial financial growth.
- Dive into the specifics of Carl Zeiss Meditec here with our thorough financial health report.
Where To Now?
- Click through to start exploring the rest of the 196 Undervalued European Stocks Based On Cash Flows now.
- Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
- Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Contemplating Other Strategies?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if ASML Holding might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com